INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,254 | -17.7% | 600 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $37,992 | +16.9% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $32,490 | +2.3% | 600 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $31,752 | +13.4% | 600 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $28,000 | -17.6% | 600 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $34,000 | -8.1% | 600 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $37,000 | +19.4% | 600 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $31,000 | +40.9% | 600 | 0.0% | 0.00% | +50.0% |
| Q3 2021 | $22,000 | +633.3% | 600 | +200.0% | 0.00% | – |
| Q4 2017 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | – |
| Q3 2017 | $3,000 | +50.0% | 200 | 0.0% | 0.00% | – |
| Q2 2017 | $2,000 | -33.3% | 200 | 0.0% | 0.00% | – |
| Q1 2017 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | -100.0% |
| Q4 2016 | $3,000 | 0.0% | 200 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $3,000 | -62.5% | 200 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $8,000 | – | 200 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |